{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:58:30Z","timestamp":1791172710280,"version":"4.1.0"},"reference-count":48,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,4,5]],"date-time":"2010-04-05T00:00:00Z","timestamp":1270425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:p>The development of effective immunoadjuvants for tumor immunotherapy is of fundamental importance. The use of <jats:italic>Mycobacterium bovis<\/jats:italic> bacillus Calmette\u2010Gu\u00e9rin cell wall skeleton (BCG\u2010CWS) in tumor immunotherapy has been examined in various clinical applications. Because BCG\u2010CWS is a macromolecule that cannot be chemically synthesized, the development of an alternative synthetic molecule is necessary to ensure a constant supply of adjuvant. In the present study, a new adjuvant was designed based on the structure of macrophage\u2010activating lipopeptide (MALP)\u20102, which is a Toll\u2010like receptor (TLR)\u20102 ligand similar to BCG\u2010CWS. Macrophage\u2010activating lipopeptide\u20102, [S\u2010(2,3\u2010bispalmitoyloxypropyl)Cys (P2C) \u2013 GNNDESNISFKEK], originally identified in a Mycoplasma species, is a lipopeptide that can be chemically synthesized. A MALP\u20102 peptide was substituted with a functional motif, RGDS, creating a novel molecule named P2C\u2010RGDS. RGDS was selected because its sequence constitutes an integrin\u2010binding motif and various integrins are expressed in immune cells including dendritic cells (DCs). Thus, this motif adds functionality to the ligand. P2C\u2010RGDS activated DCs and splenocytes more efficiently than MALP\u20102 over short incubation times <jats:italic>in vitro<\/jats:italic>, and the RGDS motif contributed to their activation. Furthermore, P2C\u2010RGDS showed higher activity than MALP\u20102 in inducing migration of DCs to draining lymph node, and in inhibiting tumor growth <jats:italic>in vivo<\/jats:italic>. This process of designing and developing synthetic adjuvants has been named \u201cadjuvant engineering,\u201d and the evaluation and improvement of P2C\u2010RGDS constitutes a first step in the development of stronger synthetic adjuvants in the future. (<jats:italic>Cancer Sci<\/jats:italic> 2010)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2010.01583.x","type":"journal-article","created":{"date-parts":[[2010,5,7]],"date-time":"2010-05-07T08:02:10Z","timestamp":1273219330000},"page":"1596-1603","source":"Crossref","is-referenced-by-count":20,"title":["Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion"],"prefix":"10.1111","volume":"101","author":[{"given":"Takashi","family":"Akazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Seya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecam\/nek010"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605978104"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.4.316"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1100"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1652"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1589"},{"issue":"6","key":"e_1_2_6_8_2","first-page":"4369","article-title":"Role of toll\u2010like receptors and their adaptors in adjuvant immunotherapy for cancer","volume":"23","author":"Seya T","year":"2003","journal-title":"Anticancer Res"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.015"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.7.4612"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1112"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4889(01)00182-3"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/35047123"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/52.1.95"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.74.50"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.11.7096"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.12.6883-6890.2000"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.8.4238-4249.2003"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-1518"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-008-3826-3"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.2.937-948.2004"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(01)00071-6"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00070-4"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/7.7.1135"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04808"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.08.018"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.11.7175"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.12.7571"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406740101"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.026005"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00832.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.11.1951"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.3.1657-1665.2004"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M504320200"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737537"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.5.665"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1105694"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700586"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.9.5688"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.11.6500"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2007.06.019"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.20.12407"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.4.2610"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.48.589"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3011.2005.00242.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80348-9"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600141"},{"issue":"21","key":"e_1_2_6_48_2","first-page":"6146","article-title":"Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model","volume":"62","author":"Janssen ML","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1286-4579(02)01610-6"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2010.01583.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2010.01583.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:25:48Z","timestamp":1697376348000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2010.01583.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,14]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1349-7006.2010.01583.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01583.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,14]]}}}